Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.35 |
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 2/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12060769 | 0.99 | SIGMAR1 (0.36) | SIGMAR1PDE5ACYP1A1CYP1A2CYP1B1 | |
| SCHEMBL12060556 | 0.97 | SIGMAR1 (0.37) | SIGMAR1PDE5ACYP1A1CYP1A2CYP1B1 | |
| SCHEMBL12060868 | 0.97 | SIGMAR1 (0.37) | SIGMAR1PDE5ACYP1A1CYP1A2CYP1B1 | |
| SCHEMBL12060562 | 0.96 | SIGMAR1 (0.38) | SIGMAR1PDE5AITKABCG2 | |
| SCHEMBL12567697 | 0.93 | SIGMAR1 (0.36) | SIGMAR1PDE5ACYP1A1CYP1A2CYP1B1 | |
| SCHEMBL12060768 | 0.92 | SIGMAR1 (0.37) | SIGMAR1PDE5ACYP1A1CYP1A2CYP1B1 | |
| SCHEMBL12060264 | 0.92 | SIGMAR1 (0.37) | SIGMAR1PDE5A | |
| SCHEMBL12060553 | 0.92 | SIGMAR1 (0.40) | SIGMAR1PDE5AITK | |
| SCHEMBL12048510 | 0.90 | SIGMAR1 (0.42) | SIGMAR1PDE5ACYP1A1CYP1A2CYP1B1 | |
| SCHEMBL12060521 | 0.89 | SIGMAR1 (0.39) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110127495-A1 | NEW COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME | LG CHEM, LTD. (KR) | 2011-06-02 | — | — | US | disclosed |
| US-7816019-B2 | Compound and organic light emitting device using the same | LG CHEM, LTD. (KR) | 2010-10-19 | — | — | US | disclosed |
| US-20090045721-A1 | Compound and organic light emitting device using the same | LG CHEM, LTD. (KR) | 2009-02-19 | — | — | US | disclosed |
| US-20080093982-A1 | Compound and Organic Light Emitting Device Using the Same | LG CHEM, LTD. (KR) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110127495-A1 | NEW COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME | PPOX, CYBA, CRY1 | SIGMAR1 3635/4885PDE5A 3661/4885CYP1A1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.